Marpai, Inc. (MRAI) Stock Price & Analysis
Marpai, Inc. (MRAI) rose 8.22% to USD 2.37 as of July 25, 2026 at 08:20 UTC, according to Nexqual real-time market data.
MRAI last closed at USD 2.19; the session ranged USD 2.12–2.5 on volume of 135,210 shares. Market capitalization is $59.94M, with a 52-week range of USD 0.22–2.5 (OQX). Source: Nexqual, July 25, 2026 at 08:20 UTC.
Key Statistics (as of July 25, 2026 at 08:20 UTC)
| Price | USD 2.37 |
|---|---|
| Change | ▲ 8.22% (up) |
| Previous Close | USD 2.19 |
| Open | USD 2.15 |
| Day Range | USD 2.12 – 2.5 |
| 52-Week Range | USD 0.22 – 2.5 |
| Volume | 135,210 shares |
| Market Cap | $59.94M |
| Exchange | OQX |
Technical Analysis (MRAI)
Nexqual's technical model rates MRAI "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 08:20 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 76.78 (overbought) |
| vs SMA50 | Above (USD 0.78) |
| MACD | 0.4 (positive) |
Analyst Ratings (MRAI)
Wall Street analysts rate MRAI "None", per Nexqual as of July 25, 2026 at 08:20 UTC.
| Consensus Rating | None |
|---|
Earnings (MRAI)
| Next Earnings Date | 2026-08-12 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-03-31 | USD -0.46 vs est -0.43 ▼ miss |
| 2023-12-31 | USD -0.09 vs est -0.19 ▲ beat |
| 2023-09-30 | USD -0.97 vs est -0.79 ▼ miss |
| 2023-06-30 | USD -1.05 vs est -0.95 ▼ miss |
Source: Nexqual, July 25, 2026 at 08:20 UTC.
Financials & Fundamentals (MRAI)
| Total Revenue | $17.13M |
|---|---|
| Revenue Growth (YoY) | -18.00% |
| Gross Margin | +23.66% |
| Operating Margin | -55.90% |
| Profit Margin | -97.37% |
| Current Ratio | 0.38 |
| Total Cash | $201,000 |
| Total Debt | $28.95M |
| Free Cash Flow | $-430,750 |
Source: Nexqual, July 25, 2026 at 08:20 UTC.
Financial Health Score (MRAI)
Nexqual rates Marpai, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 08:20 UTC.
| Growth | Strong — Revenue +53% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $201K cash vs $29M debt |
| Cash Flow | Weak — FCF negative: -$431K, burning cash |
| Efficiency | Mixed — No data |
Ownership (MRAI)
| Insider Ownership | +51.23% |
|---|---|
| Institutional Ownership | +4.07% |
| Shares Outstanding | 25.29M |
| Float | 12.42M |
| Short % of Float | +0.24% |
Source: Nexqual, July 25, 2026 at 08:20 UTC.
Leadership (MRAI)
Marpai, Inc. is led by Damien Francis Lamendola (age 69), President, CEO & Director, per Nexqual as of July 25, 2026 at 08:20 UTC.
| President, CEO & Director | Damien Francis Lamendola (age 69) |
|---|---|
| CFO & Company Secretary | Steve Johnson (age 54) |
| Co-Founder & Independent Chairman of the Board | Yaron I. Eitan (age 69) |
| Chief Strategy Officer | Richard Brewer |
| President of MarpaiRx | Mimi Davis |
Major Backers & Investors (MRAI)
Notable institutional backers of Marpai, Inc. include FNY Investment Advisers, LLC, according to Nexqual as of July 25, 2026 at 08:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FNY Investment Advisers, LLC | 0.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.88% |
Source: Nexqual, July 25, 2026 at 08:20 UTC.
From Marpai, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Marpai, Inc., together with its subsidiaries, operates as a technology-driven healthcare payer company in the United States.
- The company provides third-party administrator and value-oriented health plan services to employers that directly pay for employee health benefits.
- It also offers in-house ancillary services that include clinical care management, a nurse-led guide for at-risk members across the care continuum; repricing insights, which are out-of-network claims; Marpai PACCS, a pharmacy advocacy cost containment solution that is a member-driven pharmacy savings program; and MarpaiRx, a national pharmacy benefit management program.
- In addition, the company provides health plan administration services, third-party vendor services, and complementary services, such as case management, actuarial, and bill review services.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CNTX | Context Therapeutics Inc. | USD 0.61 | ▲ 0.18% |
| PXMD | PaxMedica, Inc. | USD 0 | ▲ 0% |
| SMFL | Smart for Life, Inc. | USD 0 | ▲ 0% |
| STRN | SMART Trend 25 ETF | USD 26.23 | ▼ 2.92% |
| SNTG | Sentage Holdings Inc. | USD 2.17 | ▲ 1.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:20 UTC. This page is informational and not investment advice.